Albany Molecular Research Inc
AMRI
AMRI was delisted on the 31st of August, 2017.
132 hedge funds and large institutions have $484M invested in Albany Molecular Research Inc in 2014 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 50 increasing their positions, 39 reducing their positions, and 30 closing their positions.
200% more call options, than puts
Call options by funds: $3.57M | Put options by funds: $1.19M
28% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 39
8% less funds holding
Funds holding: 143 → 132 (-11)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
28% less capital invested
Capital invested by funds: $669M → $484M (-$185M)
33% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
+$36.7M |
| 2 |
VNIM
Vaughan Nelson Investment Management
Houston,
Texas
|
+$24.5M |
| 3 |
PIP
Permian Investment Partners
Dallas,
Texas
|
+$16.3M |
| 4 |
IGM
Incline Global Management
New York
|
+$8.53M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$7.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$19.3M |
| 2 |
BM
Bridger Management
New York
|
-$18M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$13.8M |
| 4 |
Millennium Management
New York
|
-$12.9M |
| 5 |
CPIM
Columbia Partners Investment Management
Alexandria,
Virginia
|
-$12.3M |
AMRI Hedge Fund Activity: Q4 2014 in Review
132 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Albany Molecular Research Inc (AMRI) for Q4 2014, worth a combined $484M — down 28% from $669M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of AMRI and 20 opened new positions — a net loss of 10 holders — while 39 trimmed existing stakes and 50 added.
The largest buyer was Visium Asset Management, adding an estimated $36.7M. The largest seller was Morgan Stanley, cutting an estimated $19.3M.
- 132 institutional investors held Albany Molecular Research Inc (AMRI) as of Q4 2014, down from 143 in Q3 2014.
- Funds reported $484M of Albany Molecular Research Inc stock for Q4 2014, down 28% quarter-over-quarter.
- 20 funds opened new Albany Molecular Research Inc positions in Q4 2014 and 30 closed out, a net change of -10 holders.
- The largest Albany Molecular Research Inc buyer in Q4 2014 was Visium Asset Management, an estimated $36.7M added.
- The largest Albany Molecular Research Inc seller in Q4 2014 was Morgan Stanley, an estimated $19.3M sold.
Based on aggregated 13F filings for Q4 2014.